Mirror PR to Forgejo / mirror (pull_request) Waiting to run

Details

vida: extract claims from 2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics

- Source: inbox/queue/2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics.md
- Domain: health
- Claims: 0, Entities: 4
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

2026-05-11 04:28:15 +00:00

1.5 KiB

Raw Blame History

INVI MindHealth

Location: Denver, Colorado

Focus: Real-time biomarker platform for neuromodulation and psychedelic therapies

Stage: Selected for ARPA-H EVIDENT initiative

Technology Platform

Real-time biomarker monitoring system designed to:

Track physiological responses during neuromodulation treatments
Monitor psychedelic therapy sessions
Generate FDA-ready clinical endpoint data

Strategic Position

INVI MindHealth represents the biomarker infrastructure layer for behavioral health interventions—addressing the measurement gap that has historically limited psychedelic and neuromodulation research. Real-time monitoring enables:

Objective outcome measurement beyond self-reported scales
Safety monitoring during treatment sessions
Dose-response optimization
Mechanistic understanding of therapeutic effects

Timeline

2026-04-24 — Selected as ARPA-H EVIDENT research team for real-time biomarker platform development

Analysis

The biomarker platform addresses a critical gap in psychedelic research: functional unblinding (patients and clinicians knowing who received active drug) invalidates self-reported outcomes in highly psychoactive compounds. Objective biomarkers could provide unblinding-resistant endpoints, strengthening regulatory submissions.

ARPA-H's selection of a biomarker platform company (rather than only drug developers) signals recognition that measurement infrastructure is a binding constraint on FDA approval pathways for behavioral health interventions.

1.5 KiB Raw Blame History